Search Result

Results for "

Respiratory symptoms

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) CFTR (2) Chloride Channel (2) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Endonuclease (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (2) Reactive Oxygen Species (ROS) (1) SARS-CoV (1)
By Research Areas:	Infection (1) Inflammation/Immunology (4) Neurological Disease (5)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: RSV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107355

Letosteine	Reactive Oxygen Species (ROS)	Inflammation/Immunology
Letosteine is an orally active, potent and safe expectorant. Letosteine has the effect of scavenging reactive oxygen species (ROS). Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research .

HY-108858

Dornase alfa 1 Publications Verification rhDNase	DNA/RNA Synthesis Endonuclease	Inflammation/Immunology
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase) that can specifically degrade extracellular DNA. Dornase alfa catalyzes the cleavage of DNA released by neutrophils in respiratory mucus, reduces sputum viscosity, thereby improving mucus clearance efficiency, reducing airway obstruction and alleviating inflammatory responses. Dornase alfa can be used to improve lung function (such as FEV_1) in cystic fibrosis (CF), reduce the risk of acute pulmonary exacerbations, and has good in vivo tolerability. Dornase alfa acts locally on the respiratory tract through aerosol inhalation, specifically improving the high viscosity of mucus caused by DNA accumulation and related respiratory symptoms .

HY-B1032

Dropropizine (±)-Dropropizine; UCB-196	Others	Neurological Disease
Dropropizine ((±)-Dropropizine; UCB-196) is an orally effective, peripherally selective antitussive that inhibits the activity of peripheral receptors and afferent nerves in the respiratory tract. Dropropizine acts on the cough reflex pathway, does not pass the blood-brain barrier, and has no central nervous system side effects. Dropropizine mainly regulates the level of sensory neuropeptides and inhibits the afferent signal transmission of the cough reflex, thereby alleviating the symptoms of dry cough, and has both mild local anesthetic and antihistamine activity. Dropropizine is mainly used for symptomatic research on dry cough caused by respiratory diseases .

HY-W008719

MPP+ iodide 15+ Cited Publications	Mitochondrial Metabolism	Neurological Disease
MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .

HY-145603

Vanzacaftor VX-121	CFTR Chloride Channel	Neurological Disease
Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

HY-W008719S

MPP+-d3(iodide)	Mitochondrial Metabolism	Neurological Disease
MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .

HY-113749

L-Mabuterol hydrochloride	Adrenergic Receptor	Inflammation/Immunology
L-Mabuterol hydrochloride is a selective β2-adrenergic receptor agonist with bronchodilator activity. L-Mabuterol hydrochloride can improve respiratory function and relieve asthma symptoms. L-Mabuterol hydrochloride also shows potential efficacy in the management of chronic obstructive pulmonary disease (COPD) .

HY-W074888

N-Lauroyl-L-glutamic acid	Endogenous Metabolite	Inflammation/Immunology
N-Lauroyl-L-glutamic acid is an amino acid derivative with anti-asthmatic activity. N-Lauroyl-L-glutamic acid has been found to improve asthma symptoms in studies. The potential application of N-Lauroyl-L-glutamic acid is mainly focused on the suppression of respiratory diseases. N-Lauroyl-L-glutamic acid may help improve the quality of life of patients .

HY-109072

Riamilovir	SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2 .

HY-145603S

Vanzacaftor-d4 VX-121-d₄	Isotope-Labeled Compounds CFTR Chloride Channel	Neurological Disease
Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

Cat. No.	Product Name	Chemical Structure

HY-W008719S

MPP+-d3(iodide)
MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .

MPP+-d3(iodide)

MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .

HY-145603S

Vanzacaftor-d4
Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

Vanzacaftor-d4

Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.